Innovent's Avastin Biosimilar Matches Efficacy of Original in Phase III Trial

Innovent Biologics of Suzhou announced its Avastin (bevacizumab) biosimilar produced similar results to the original drug in a double blind Phase III trial. Both drugs were administered together with paclitaxel/carboplatin as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). Innovent presented the data at the Chinese Society of Clinical Oncology (CSCO) earlier today. In late 2018, Innovent was approved to market its PD-1 drug, Tyvyt®, in China, the company's first launched product. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //